Does Folotyn® work in NSCLC? Allos Therapeutics Reports Phase 2 Results
On Wednesday the 28th Allos announced the results of their randomized phase 2 study comparing Folotyn
(more)
July 29, 2010
July 12, 2010
Buying Opportunities? Dendreon; Antisoma
On July 1st CMS announced that Dendreon’s Provenge® will undergo a National Coverage Determination (NCD).
(more)